Rasagiline
- Generic Name
- Rasagiline
- Brand Names
- Azilect, Rasagiline Mylan, Rasagiline ratiopharm
- Drug Type
- Small Molecule
- Chemical Formula
- C12H13N
- CAS Number
- 136236-51-6
- Unique Ingredient Identifier
- 003N66TS6T
Overview
Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.
Background
Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.
Indication
For the treatment of the signs and symptoms of idiopathic Parkinsons disease as initial monotherapy and as adjunct therapy to levodopa.
Associated Conditions
- Parkinson's Disease (PD)
Clinical Trials
FDA Approved Products
Rasagiline mesylate
Manufacturer:Avet Pharmaceuticals Inc.
Route:ORAL
Strength:0.5 mg in 1 1
Approved: 2023/10/25
NDC:23155-746
Rasagiline mesylate
Manufacturer:Avet Pharmaceuticals Inc.
Route:ORAL
Strength:1 mg in 1 1
Approved: 2023/10/25
NDC:23155-747
Rasagiline
Manufacturer:Ascend Laboratories, LLC
Route:ORAL
Strength:1 mg in 1 1
Approved: 2021/11/30
NDC:67877-260
Rasagiline
Manufacturer:Ascend Laboratories, LLC
Route:ORAL
Strength:0.5 mg in 1 1
Approved: 2021/11/30
NDC:67877-259
Rasagiline
Manufacturer:Alvogen, Inc.
Route:ORAL
Strength:0.5 mg in 1 1
Approved: 2019/03/27
NDC:47781-683
Singapore Approved Products
AZILECT TABLET 1MG
Manufacturer:Teva Pharmaceutical Industries, Ltd.
Form:TABLET
Strength:1 MG
Online:Yes
Approved: 2017/07/07
Approval:SIN15291P
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.
© Copyright 2025. All Rights Reserved by MedPath